Home › Funds › Affinity Asset Advisors, LLC › PTGX
Affinity Asset Advisors, LLC position in PTGX
PROTAGONIST THERAPEUTICS INC · Health Care
Affinity Asset Advisors, LLC reported holding 172,125 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$24.3M, representing 1.13% of its reported portfolio and ranking #27 among its reported holdings. Affinity Asset Advisors, LLC has disclosed PTGX holdings in 9 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Affinity Asset Advisors, LLC's PTGX position evolved
Affinity Asset Advisors, LLC first disclosed a stake in PTGX in Q1 2024 at 100,000 shares (US$2.9M). The position peaked in Q2 2025 at 440,000 shares, worth US$24.3M. Across 9 filings, Affinity Asset Advisors, LLC increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 172,125 shares valued at US$24.3M. Notable position changes include a 33% increase in Q1 2025 (shares rose 14% over the following quarter), a 155% increase in Q2 2025 (shares rose 20% over the following quarter), a 50% trim in Q3 2025 (shares rose 31% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 100.00K | $2.89M | New |
| Q4 2024 | 130.00K | $5.02M | New |
| Q1 2025 | 172.50K | $8.34M | Add |
| Q2 2025 | 440.00K | $24.32M | Add |
| Q3 2025 | 220.60K | $14.65M | Reduce |
| Q4 2025 | 172.12K | $15.03M | Reduce |
| Q1 2026 | 172.12K | $18.14M | Hold |
| Q2 2026 | 172.12K | $21.10M | Hold |
| Q3 2026 | 172.12K | $24.25M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PTGX and 13F data
PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 50 other funds we track also report a position in PTGX — the largest reported positions include Farallon Capital Management (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PTGX
- Farallon Capital Management 6.35M sh · $778.25M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 6.35M sh · $778.25M · Q2 2026
- RTW INVESTMENTS, LP 5.06M sh · $620.40M · Q2 2026
- JOHNSON & JOHNSON 2.45M sh · $345.07M · Q3 2026
- Woodline Partners LP 1.41M sh · $173.35M · Q2 2026
- PERCEPTIVE ADVISORS LLC 981.88K sh · $120.36M · Q2 2026
- ADAR1 Capital Management, LLC 960.86K sh · $117.78M · Q2 2026
- Hood River Capital Management LLC 882.74K sh · $108.21M · Q2 2026
- 683 Capital Management, LLC 290.00K sh · $35.55M · Q2 2026
- Eagle Health Investments LP 248.32K sh · $34.99M · Q3 2026
- NEXTBio Capital Management LP 219.33K sh · $30.90M · Q3 2026
More on Affinity Asset Advisors, LLC
FAQ
How long has Affinity Asset Advisors, LLC held PTGX?
Affinity Asset Advisors, LLC has disclosed PTGX holdings in 9 of the last 11 reported quarters, going back to Q1 2024.
What is Affinity Asset Advisors, LLC's current position in PTGX?
As of Q3 2026, Affinity Asset Advisors, LLC holds 172.12K shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $24.25M, representing 1.13% of its reported portfolio and ranking #27.
Has Affinity Asset Advisors, LLC been buying or selling PTGX?
In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC held unchanged its position in PTGX. The position peaked in Q2 2025 at 440.00K shares.
Which other funds hold PTGX?
Other major institutional holders of PTGX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 50 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.